Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | DRD4 | P21917 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 2/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | DRD5 | P21918 | 1/20 | 0.33 |
| ▸ | DRD3 | P35462 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12939844 | 1.00 | KDM2B (0.40) | KDM2BPOLBADORA2ALTA4HHRH1 | |
| SCHEMBL12939842 | 0.89 | POLB (0.36) | KDM2BPOLB | |
| SCHEMBL9969575 | 0.89 | POLB (0.36) | KDM2BPOLB | |
| SCHEMBL23976236 | 0.89 | GRIN1 (0.37) | KDM2BLTA4H | |
| SCHEMBL2249716 | 0.85 | ALOX15 (0.38) | POLBADORA2ALTA4HHRH1DRD4 | |
| Hydrochloric Acid SCHEMBL18225448 | 0.84 | POLB (0.37) | POLBADORA2ALTA4H | |
| SCHEMBL12021790 | 0.83 | DRD2 (0.47) | KDM2BDRD4DRD2DRD1DRD5 | |
| SCHEMBL23158163 | 0.83 | DRD2 (0.47) | KDM2BDRD4DRD2DRD1DRD5 | |
| SCHEMBL19617090 | 0.81 | ALDH1A1 (0.40) | KDM2BPOLB | |
| SCHEMBL23640637 | 0.81 | KDM2B (0.40) | KDM2BPOLBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| CN-102070608-A | 4-substituted phenylamino-7-substituted alkoxy-quinazoline derivant and preparation method and application thereof | TIANJIN INST PHARM RESEARCH | 2011-05-25 | — | — | CN | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | KDM2B 4851/4885POLB 1225/4885ADORA2A 2521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.